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Abstract The decade since the publication of the Human
Genome Project draft has ended with the discovery of hun-
dreds of genomic markers related to diseases and pheno-
types. However, the project has not yet delivered on its
promise to tailor treatments for individuals. The number of
genomic markers in clinical practice is very small. The
number of markers to guide treatment decisions is even
smaller. In order to speed up discovery and validation of
genomic treatment selection markers, we call for consider-
ing the brilliant potential of randomized clinical trials. If
biomedical research community can collaborate in organiz-
ing large-scale consortium of clinical trials associated with
well-designed biobanks, these studies would soon act as
huge laboratories for investigating genomic medicine; a big
step forward towards personalizing medicine.
Introduction
A common experience of practicing physicians is that only
a subgroup of patients with a speciWc disease can derive
substantial beneWt from a particular therapy. It is rare for a
drug or treatment option to be safe or eVective for every-
one. The inherent variability in treatment response among
individuals has a signiWcant eVect on the quality and cost of
health care. Spear and colleagues (2001) have analyzed the
eYcacy of major drugs for several major diseases based on
published data. They found that the highest percentage of
responding patients is between 80 for Cox-2 inhibitors and
25% for cancer chemotherapy. Many of the drugs fall
within the range of 50 to 75% response. The safety of treat-
ment options also varies between drugs and diseases.
The conspicuous variability in response, combined with
the costs and safety concerns for drugs, make it attractive,
or even necessary, to look for so-called treatment selection
markers. These are biomarkers that can prospectively iden-
tify individuals who are likely to beneWt from a speciWc
treatment, separating them from whom in which the more
limited health gains do not outweigh the safety and side
eVects of treatment.
About a decade ago, when the Wrst draft sequence of
human genome was published, hopes were raised that geno-
mic information would Wnally explain the heretofore inex-
plicable heterogeneity of treatment responses and lead to a
revolution in medicine. Francis Collins (2010), one of the
leaders of the project at the time, forecasted that in about
10 years there would be genetic markers available indicat-
ing a person’s risk of heart disease, cancer, and other com-
mon conditions, soon to be followed by individually
tailored preventive measures and therapies.
This article comments on the present and the future of
genomic discoveries for tailoring medicine. We brieXy
summarize the current state of genomic treatment selection
markers. We then discuss the potentials and partly over-
looked role of clinical trials in the discovery and validation
of genomic markers.
Genome-based treatment selection: Where are we now?
Reviewing the list of valid genomic biomarkers in the
labels of FDA approved drug products reveals that by now
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only 22 genomic markers have entered routine clinical
practice. These are some gene-targeted cancer treatments,
some predictors of drug toxicities, a few markers of drug
metabolism that have proved useful for dose adjustment,
and a gene-speciWc antiviral drug.
This number is quite small, compared with the myriad of
diseases, the plethora of existing drugs, and the global
health burden. In addition, evaluations show that most of
these genomic biomarkers were discovered well before the
sequencing of the reference human genome (McDermott
et al. 2011; Varmus 2010). In short, it seems that now, after
a decade of research, the Human Genome Project has not
yet delivered its initial promises. StratiWed medicine,
let alone personalized medicine, has not yet entered in
everyday clinical practice. Unpredictable variability in
treatment outcome remains a given in clinical decisions.
A more balanced and less sceptical assessment of the
fruits of the Human Genome Project for clinical medicine
would come to the conclusion that the discovery of more
than 1,100 genetic loci within a few years can be consid-
ered as an excellent start. In this short time, genomics have
been insightful about, for example, cancers, the molecular
basis of inherited diseases, and the role of structural varia-
tion in disease (Green and Guyer 2011). By providing a
comprehensive scaVold, the human genome sequence has
made it possible for scientists to assemble often fragmen-
tary information into landscapes of biological structure and
function (Lander 2011).
In order to translate these Wndings into improved diag-
nostics and better treatments we now need, over the next
decades, intensive functional studies to characterize the
genes and pathways underlying diseases. If this material-
izes, we expect more of the initially promised improve-
ments in the eVectiveness of healthcare. Most likely, the
initial promise was overly optimistic in terms of timing. As
Green and Guyer (2011) wrote in their updated vision of
genomic medicine “signiWcant change rarely comes
quickly”.
Association of variants at the 9p21 locus with myocar-
dial infarction can be seen as a very good example for
showing that genomic research in medicine still has to
mature. This association was one of the Wrst discoveries of
Genome Wide Association Studies (GWAS) in 2007 and
one of the most consistent and robust variant-disease asso-
ciations in the GWAS era (Schunkert et al. 2008). How-
ever, scientists neither have any hypotheses for the function
of the locus nor could they explain why it was associated
with increased risk of cardiovascular diseases. It was only
known that the locus was located in a gene desert, with the
nearest protein-coding region several thousand kilobases
away. Continued investigations have recently shown an
important regulatory function of the 9p21 gene desert in
response to inXammatory signalling in vascular cell types,
an important pathway in understanding the disease etiology
and its treatment (Harismendy et al. 2011).
From cohort studies to clinical trials
As forecasted in the National Human Genome Research
Institute vision for the future of genomics research, the pro-
gress during the second decade will be mainly focused on
understanding the biology of genomes and diseases.
Improving the eVectiveness of clinical medicine can only
be expected to happen beyond 2020 (Green and Guyer
2011).
Converting scientiWc discoveries into improved medical
tests and more eVective treatments for clinical practice have
always been slow and diYcult. To harmonize and acceler-
ate the eVorts for translating genomic discoveries into
health care, Khoury and colleagues (2007) proposed a four-
phase framework. Phase 1 moves a basic genomic discov-
ery into a candidate health application (e.g., genetic test or
intervention); Phase 2 assesses the value of the genomic
application for health practice leading to the development
of evidence-based guidelines. Phases 3 and 4 introduce evi-
dence-based guidelines into health practice and evaluate the
outcomes in the real world.
At present, the driving engine of genomic discoveries in
Phase 1 is formed by large-scale collaborative cohorts
(Psaty and Hofman 2010) or case–control studies, which
have the genotype information of their participants. The
output of these studies consists of genomic markers that
have robust associations with the studied diseases or traits.
There have been similar eVorts to identify putative treat-
ment selection markers through studying cohorts of treated
patients and Wnding genomic markers that are associated
with the response to treatment. For example, O’Doherty
and colleagues (2009) analyzed 61 SNPs in 34 candidate
genes as possible determinants of IFN-beta response in 255
relapsing–remitting multiple sclerosis patients. The authors
compared genotype and allele frequencies between
responders and nonresponders. Yet, the mere identiWcation
of allelic combinations that diVer signiWcantly between
responders and nonresponders do not qualify these as
multi-allele treatment selection markers. For that purpose,
one has to compare the beneWt from treatment for marker-
positive patients, identiWed as such before treatment starts,
and marker-negative patients (Janes et al. 2011).
The best way to identify treatment selection markers
would be in randomized comparative clinical trials. This
assures that the patients who were treated with the agent for
whom the marker is purported to be predictive are compa-
rable to those who were not. In a nonrandomized design, it
is impossible to isolate any causal eVect of the marker on
therapeutic eYcacy from the multitude of other factors thatHum Genet (2011) 130:15–18 17
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may inXuence the decision to treat or not to treat a patient
(Mandrekar and Sargent 2009).
Looking for markers of treatment beneWt in randomized
trials is an excellent strategy for accelerating genomic
marker discoveries, but it is also helpful in validating them
for clinical applications. MINDACT, for example, is a trial
designed for validating a genomic signature for breast can-
cer. The trial is expected to enroll 6,000 breast cancer
patients to evaluate whether risk assessment by a 70-gene
proWle can improve risk assessment avoiding non-neces-
sary chemotherapy for the low risk patients (Bogaerts et al.
2006). The study was launched in 2007 and the estimated
primary completion date is 2019.
A simple search in Pubmed will show that only about 2%
of present research publications in the Weld of human genom-
ics have been classiWed by the National Library of Medicine
as clinical trials reports, most of which are not randomized
trials. A landmark example of a genomic marker that has
been successfully discovered and validated using RCTs is
KRAS. This genomic marker is the predictor of the eYcacy
of panitumumab and cetuximab in advanced colorectal can-
cer. In an analysis of data from a randomized phase 3 trial of
panitumumab versus the best supportive care, KRAS status
was assessed on archived tumor specimens of about 400
enrolled patients (Amado et al. 2008). This analysis demon-
strated a statistically signiWcant advantage in the overall sur-
vival for patients with wild-type KRAS on panitumumab,
whereas patients with mutant-type KRAS enjoyed no sur-
vival beneWt. In addition, multiple phase 2 trials consistently
demonstrated similar results (Mandrekar and Sargent 2009).
The American Society of Clinical Oncology estimates that
routinely testing people with colon cancer for mutations in
the KRAS oncogene would save at least $600 million a year,
demonstrating how timely translation of genomic markers
could increase health care eYciency (Poste 2011).
From individual trials to prospective meta-analysis 
with biobanking
One important obstacle in using clinical trials for discovery
and validation of genomic markers is the large sample sizes
needed for such analyses. Few studies have enough partici-
pants to provide adequate statistical power, particularly in
view of the multiple-testing inherent in genetic analyses.
Cohorts and well-conducted case–control studies have suc-
cessfully adapted to the genomics era by forming large-
scale consortia. Some consortia comprise more than a mil-
lion participants, which helps in overcoming the limitations
associated with the large volume of genomic data and in
allowing for continued genomic discoveries. The consortia
provide the opportunity to prospectively plan meta-analyses
and Wnd independent studies for replication of the Wndings
(Psaty and Hofman 2010). Now it is time for clinical trials
to take their role in genomic era and move seriously toward
forming large-scale consortia.
A very interesting development is the increasing use of
prospective meta-analysis of randomized trials, a form of
meta-analysis in which trials are identiWed, evaluated and
determined to be eligible before the results of any of those
studies became known (PfeVer et al. 2003; The PPP Project
Investigators  1995). Such collaborative projects allow
a priori coordination of data collection eVorts, entry selec-
tion criteria and end-points, prospective harmonizing of
collected data, and preplanned data pooling. Prospective
meta-analysis of individual patient data in large RCTs may
result in the sample size required to test hypotheses about
genomic markers for treatment selection. When the pooling
process was planned as an initial step in clinical trials, such
as in the Cholesterol Treatments Trialists’(CTT) Collabora-
tion, with about 170,000 recruitments (Baigent et al. 2010),
it has succeeded. Major companies have also realized the
importance of such cooperation. Merck, Eli Lilly, and
PWzer have planned a joint Asian Cancer Research Group
that will help speed up research on new drugs to treat gas-
tric and lung cancers (Lancet Editorial Board 2011).
The presence of RCT registries is an exceptional oppor-
tunity for prospective meta-analysis, one that does not exist
for other study types. Although trial registration is in place
to increase transparency with respect to performance and
reporting of clinical trials (ICMJE 2004), it can now also
perform as an excellent platform for the formation of the
core of large-scale RCT consortia. Registries can serve as
search engines for Wnding suitable studies for the replica-
tion and validation of the genomic markers.
Another key necessity for the discovery of genomic
treatment selection markers is generating biobanks that
accompany clinical trials. Preserving biological specimens
from trial patients can be expensive to initiate and maintain,
and there may be practical and ethical considerations
related to biobanking, but these issues should not discour-
age investigators from taking on the challenge. Biobanks
allow precise future genomic investigations, which may be
beyond imagination or technical possibilities at the time of
collection. If standardized procedures are used for speci-
men collection, handling and storage, the anticipated scien-
tiWc gain from biobanks combined with thorough trial
databases would be enormous, deserving the investment
(Gustafsson et al. 2010; Poste 2011).
The presence of large RCT consortia associated with
well-designed biobanks would have the capacity to perform
as a laboratory, allowing for continued discoveries and
validation of genomic markers. This approach can potentially
save a lot of time and expenses required for conducting tri-
als for validating each newly discovered marker. So, a
more feasible and timely option to speed up the translation18 Hum Genet (2011) 130:15–18
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process of discovered genomic markers would be using data
from previously well-conducted randomized controlled tri-
als. Retrospective validation—like KRAS validation—can
aid, when conducted appropriately, in bringing forward
eVective treatments for marker-deWned patient sub-groups
in a timely manner that might otherwise be impossible
because of ethical and logistical considerations. In particu-
lar, if such a retrospective validation can be demonstrated
in data from two independent RCTs, this provides a strong
evidence for a robust predictive eVect (Mandrekar and
Sargent 2009). Regarding the expected sudden growth of
the number of discovered genomic markers in near future,
retrospective use of RCTs seems an intelligent shortcut for
keeping the translational research in a proportional pace as
the discoveries occur.
Conclusion
The high hopes that genomic information would explain the
heterogeneity of treatment responses and revolutionize
health care, leading it into an era of stratiWed or even per-
sonalized medicine, have not been met so far. The number
of validated genetic treatment selection markers is small in
number and applies to a fraction of health care. Yet, there
are reasons to remain optimistic. In the years to come,
investigators designing and conducting clinical trials have
an ethical and Wnancial responsibility to maximize the sci-
entiWc knowledge gained from the participation of the sub-
jects. Designing biobanks and collaborating with other
investigators in forming large data sets would enormously
increase the generation of evidence needed for the discov-
ery and validation of treatment selection markers. Even if
only a fraction of more than four million subjects enrolled
worldwide in interventional trials were to be captured, the
potential for progress would be enormous.
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